ATE332145T1 - MEDICATIONS FOR THE ADDITIONAL TREATMENT OF GLAUCOMA - Google Patents

MEDICATIONS FOR THE ADDITIONAL TREATMENT OF GLAUCOMA

Info

Publication number
ATE332145T1
ATE332145T1 AT00978074T AT00978074T ATE332145T1 AT E332145 T1 ATE332145 T1 AT E332145T1 AT 00978074 T AT00978074 T AT 00978074T AT 00978074 T AT00978074 T AT 00978074T AT E332145 T1 ATE332145 T1 AT E332145T1
Authority
AT
Austria
Prior art keywords
glaucoma
medications
additional treatment
active ingredients
treatment
Prior art date
Application number
AT00978074T
Other languages
German (de)
Inventor
Tomihisa Yokoyama
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE332145T1 publication Critical patent/ATE332145T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

An agent for the prophylaxis or treatment of glaucoma, which comprises an angiotensin II antagonist and at least one compound selected from adrenaline receptor blockers, prostaglandins and carbonic anhydrase inhibitors as active ingredients for simultaneous, separate or successive use of these active ingredients.
AT00978074T 1999-12-01 2000-12-01 MEDICATIONS FOR THE ADDITIONAL TREATMENT OF GLAUCOMA ATE332145T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34152499 1999-12-01
JP2000078769 2000-03-21

Publications (1)

Publication Number Publication Date
ATE332145T1 true ATE332145T1 (en) 2006-07-15

Family

ID=26576988

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00978074T ATE332145T1 (en) 1999-12-01 2000-12-01 MEDICATIONS FOR THE ADDITIONAL TREATMENT OF GLAUCOMA

Country Status (22)

Country Link
US (4) US7307096B2 (en)
EP (3) EP1344535A3 (en)
JP (1) JP4000505B2 (en)
KR (3) KR20040045028A (en)
CN (3) CN1263512C (en)
AT (1) ATE332145T1 (en)
AU (1) AU773110B2 (en)
BR (1) BR0015980A (en)
CA (1) CA2392804C (en)
CZ (1) CZ20021829A3 (en)
DE (1) DE60029242T2 (en)
ES (1) ES2267586T3 (en)
HK (1) HK1047239B (en)
HU (1) HUP0204049A3 (en)
IL (2) IL149444A0 (en)
MX (1) MXPA02005505A (en)
NO (1) NO20022584L (en)
NZ (1) NZ518930A (en)
PL (1) PL201783B1 (en)
RU (4) RU2002114335A (en)
TW (1) TWI290470B (en)
WO (1) WO2001039805A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100875908B1 (en) * 2001-04-19 2008-12-26 테이카 세이야쿠 가부시키가이샤 Drugs and Pharmaceutical Kits
TW200305424A (en) * 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
US20050119299A1 (en) * 2002-03-08 2005-06-02 Sankyo Company, Limited Ophthalmic solutions containing tetrazole derivatives
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
ES2431640T3 (en) * 2003-08-21 2013-11-27 Sucampo Ag Ophthalmic composition comprising isopropyl ester of unoprostone and a viscosity agent
WO2005079809A1 (en) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. Transparent latanoprost eye drops
JP2005263792A (en) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd Clear latanoprost ophthalmic solution
JPWO2007105691A1 (en) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ Aqueous composition
RU2339384C1 (en) * 2007-10-18 2008-11-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Viscoelastic for protection of intraocular tissues
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
RU2411946C1 (en) * 2009-07-06 2011-02-20 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Viscoprotector for protection of intraocular tissues
US20130267591A1 (en) * 2010-05-07 2013-10-10 Sun Pharma Advanced Research Company Limited Novel ophthalmic compositions
RU2443416C2 (en) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Eye drops
WO2012100347A1 (en) * 2011-01-24 2012-08-02 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
KR101327267B1 (en) 2012-04-26 2013-11-11 한양대학교 에리카산학협력단 Driving force transmission apparatus for end-effector
CN107645951B (en) 2014-11-25 2021-05-04 艾克思摩尔有限公司 Compositions and methods for delivering one or more biologically active agents
JP5951922B1 (en) * 2014-12-12 2016-07-13 興和株式会社 Aqueous composition

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619370A (en) 1969-04-21 1971-11-09 Frosst & Co Charles E Microbial reduction of thiadiazoles
JPS4966691A (en) 1972-10-30 1974-06-27
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
DE3568431D1 (en) * 1984-12-12 1989-04-06 Merck & Co Inc Substituted aromatic sulfonamides, their preparation and ophthalmic compositions containing them
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
JP2610619B2 (en) * 1987-07-22 1997-05-14 エーザイ株式会社 Eye drops for the treatment of ocular hypertension
JPS6426518U (en) 1987-08-11 1989-02-15
WO1990002553A1 (en) 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
WO1990002533A2 (en) 1988-09-09 1990-03-22 Klaus Draenert Hip-joint prosthesis and use thereof
EP0375299A1 (en) * 1988-12-19 1990-06-27 Merck & Co. Inc. Combinations of angiotensin converting enzyme, and carbonic anhydrase, inhibitors for treating glaucoma
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
US5273976A (en) * 1989-04-06 1993-12-28 Sankyo Company, Limited Ocular hypotensive agents
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
US5250521A (en) * 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
IL104648A0 (en) 1992-02-13 1993-06-10 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a prostaglandin or prostaglandin derivative
WO1993016701A2 (en) * 1992-02-21 1993-09-02 Alcon Laboratories, Inc. Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
ATE300287T1 (en) * 1994-02-08 2005-08-15 Novartis Pharma Gmbh TREATING NORMAL PRESSURE GLAUCOMA WITH VALSARTAN
CA2185524C (en) * 1994-03-16 2006-12-05 Sankyo Company Limited Ocular tension depressant
CZ284395B6 (en) * 1994-03-16 1998-11-11 Sankyo Company Limited Eye pressure reducing agent
US5760249A (en) * 1995-08-29 1998-06-02 Merck & Co., Inc. Synthesis of hydroxysulfone and related compounds
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
EP0914158B2 (en) * 1996-04-05 2006-01-25 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii antagonistic activity and a compound which increases the insulin-sensitivity
AR002194A1 (en) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany COMPUTERIZED INSTRUMENT FOR THE ANALYSIS OF MOVEMENT.
WO1998050024A1 (en) 1997-05-09 1998-11-12 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
ATE295721T1 (en) * 1999-06-11 2005-06-15 Sankyo Co EYE PRESSURE-LOWERING COMPOSITION FOR TOPICAL USE

Also Published As

Publication number Publication date
US20030040529A1 (en) 2003-02-27
EP1344534A3 (en) 2004-01-02
EP1344534A2 (en) 2003-09-17
HUP0204049A2 (en) 2003-04-28
WO2001039805A1 (en) 2001-06-07
EP1344535A3 (en) 2004-01-28
DE60029242T2 (en) 2007-07-05
IL149444A0 (en) 2002-11-10
RU2002114335A (en) 2004-01-10
EP1234582A1 (en) 2002-08-28
RU2004111358A (en) 2005-09-20
CA2392804C (en) 2009-02-03
NO20022584D0 (en) 2002-05-31
BR0015980A (en) 2002-11-12
KR20020058034A (en) 2002-07-12
JP2001335511A (en) 2001-12-04
RU2299067C2 (en) 2007-05-20
EP1234582A4 (en) 2003-05-07
CA2392804A1 (en) 2001-06-07
TWI290470B (en) 2007-12-01
KR20040045029A (en) 2004-05-31
RU2004111359A (en) 2005-09-20
RU2004111357A (en) 2005-09-20
KR20040045028A (en) 2004-05-31
CN1615880A (en) 2005-05-18
CN1263512C (en) 2006-07-12
CZ20021829A3 (en) 2002-08-14
PL201783B1 (en) 2009-05-29
KR100607430B1 (en) 2006-08-02
EP1234582B1 (en) 2006-07-05
HK1047239B (en) 2006-12-08
AU1557501A (en) 2001-06-12
US20080221184A1 (en) 2008-09-11
CN1615879A (en) 2005-05-18
MXPA02005505A (en) 2002-09-02
EP1344535A2 (en) 2003-09-17
HK1047239A1 (en) 2003-02-14
IL149444A (en) 2007-06-17
US7307096B2 (en) 2007-12-11
JP4000505B2 (en) 2007-10-31
US20050014808A1 (en) 2005-01-20
AU773110B2 (en) 2004-05-20
ES2267586T3 (en) 2007-03-16
NZ518930A (en) 2003-09-26
HUP0204049A3 (en) 2006-07-28
DE60029242D1 (en) 2006-08-17
US20050043383A1 (en) 2005-02-24
CN1407903A (en) 2003-04-02
PL355431A1 (en) 2004-04-19
NO20022584L (en) 2002-07-29

Similar Documents

Publication Publication Date Title
ATE332145T1 (en) MEDICATIONS FOR THE ADDITIONAL TREATMENT OF GLAUCOMA
DE60133029D1 (en) MEANS FOR THE PREVENTION OR TREATMENT OF PSORIASI
ATE350060T1 (en) AGENTS FOR PREVENTING OR TREATING PANCREATITIS WHICH CONTAIN ANTI-IL-6 RECEPTOR ANTIBODIES AS THE ACTIVE COMPONENT
DE60019473D1 (en) (S, S) reboxetine for the treatment of peripheral neuropathies
DK1734041T3 (en) Inhibitors of the ADP Platelet Receptor
DE60107687D1 (en) CYCLPENTANOINDOLE, MIXTURES CONTAINING SUCH COMPOUNDS AND TREATMENT METHODS
EP1074268A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENTS FOR INFLAMMATORY BOWEL CONDITIONS CONTAINING IL-6 ANTAGONISTS AS AN ACTIVE INGREDIENT
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
NO20035025L (en) Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity.
NO20032902D0 (en) Medications containing aspirin
DE60228317D1 (en) N-ARYL-N'-ARYLCYCLOALKYL UREA AS MCH ANTAGONISTS FOR THE TREATMENT OF FATIBILITY
DE69935670D1 (en) TREATMENT OF DYSKINESIA BY MU-SELECTIVE OPIOIDANT AGONISTS
IT1319240B1 (en) PROCEDURE FOR SELECTIVE OLYOMERIZATION OF ETHYLENE.
DE60222168D1 (en) ANTAGONISTS OF PROSTAGLANDINE EP2 AND / OR EP4 RECEPTORS FOR THE TREATMENT OF MENORRHAGIA
ATE295183T1 (en) AGENTS FOR RELIEVING ITCH CONTAINING PGD2 ANTAGONISTS
DE602006020871D1 (en) LINEAR UREA MIMETIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSELEIDES
NO20014855D0 (en) N- (2-phenyl-4-aminobutyl) -1-naphthamides as neurokinin-1 receptor antagonists
EA200601592A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PDE4 INHIBITOR OR PDE3 / 4 AND ANTAGONIST OF HISTAMINE RECEPTOR
ATE330599T1 (en) USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ACUTE MYOCARDIC INFARCT
ATE267194T1 (en) MEDICATIONS SUITABLE FOR THE TREATMENT OF PROLIFERATIVE DISEASES
DE69932434D1 (en) Prophylaxis and treatment of autoimmune demyelinating diseases by Fas antagonists
EA200401617A1 (en) COMBINATION OF NMDA ANTAGONIST AND ACETYL CHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALCHEIMER'S Disease
DE60014915D1 (en) HYPOXANTHIN AND THIOHYPXANTHIN COMPOUNDS
DE60215947D1 (en) PYRIDINE-2-YL-METHYLAMINE DERIVATIVES FOR THE TREATMENT OF OPIATIVE VEGETABLES
TH58562A (en) Compounds for the treatment of localized ischemia.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties